Patents by Inventor Armin Giese

Armin Giese has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL COMPOUNDS FOR THE DIAGNOSIS, TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH THE AGGREGATION OF ALPHA-SYNUCLEIN
    Publication number: 20230067910
    Abstract: The present invention relates to compounds represented by general formula (Ia), (Ib), (IIa) or (IIb). These compounds are suitable for imaging alpha-synuclein and for diagnosing diseases which are associated with the aggregation of alpha-synuclein. The compounds are also useful for treating and preventing diseases which are associated with the aggregation of alpha-synuclein.
    Type: Application
    Filed: November 19, 2020
    Publication date: March 2, 2023
    Applicants: MODAG GMBH, MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.
    Inventors: Armin GIESE, Felix SCHMIDT, Daniel WECKBECKER, Andrei LEONOV, Sergey RYAZANOV, Christian GRIESINGER, Bernd PICHLER, Kristina HERFERT, Andreas MAURER, Laura KÜBLER, Sabrina BUSS
  • Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma
    Patent number: 11180518
    Abstract: The present invention relates to a compound represented by the formula (E) which is useful for treating or preventing melanoma.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: November 23, 2021
    Assignees: MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V., LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN
    Inventors: Dorothea Becker, Thomas M. Jovin, Christian Griesinger, Andrei Leonov, Sergey Ryazanov, Armin Giese, Tiago F. Outeiro, Diana F. Lazaro, Michael P. Schön, Margarete Schön
  • PHENYL-HETEROCYCLE-PHENYL DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF MELANOMA
    Publication number: 20200165279
    Abstract: The present invention relates to a compound represented by the formula (E) which is useful for treating or preventing melanoma.
    Type: Application
    Filed: May 11, 2018
    Publication date: May 28, 2020
    Applicants: MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V., LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN, GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN
    Inventors: Dorothea BECKER, Thomas M. JOVIN, Christian GRIESINGER, Andrei LEONOV, Sergey RYAZANOV, Armin GIESE, Tiago F. OUTEIRO, Diana F. LAZARO, Michael P. SCHÖN, Margarete SCHÖN
  • Drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
    Patent number: 10435373
    Abstract: The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: October 8, 2019
    Assignees: LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN, MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V.
    Inventors: Armin Giese, Uwe Bertsch, Hans Kretzschmar, Matthias Habeck, Thomas Hirschberger, Paul Tavan, Christian Griesinger, Andrei Leonov, Sergey Ryazanov, Petra Frick née Weber, Markus Geissen, Martin H. Groschup, Jens Wagner
  • Water-soluble derivatives of 3,5-diphenyl-diazole compounds
    Patent number: 10308671
    Abstract: The present invention is concerned with derivatives of 3,5-diphenyl-diazole compounds, which are effective therapeutic agents for use in treating diseases linked to protein aggregation and/or neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and Transmissible spongiform encephalopathies (TSEs) such as Creutzfeldt-Jakob disease (CJD). The therapeutic effect is caused by the inhibition of the protein aggregation in the affected tissue, such as the brain. 3,5-Diphenyl-diazole derivatives have been shown to be effective in inhibiting aggregation of proteins but are also characterized by their poor solubility in aqueous solutions. The prodrugs of the invention are modified 3,5-diphenyl-diazole derivatives, which are characterized by their improved solubility in aqueous solutions, and by their increased bioavailability.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: June 4, 2019
    Assignee: Max-Planck-Gesellschaft zur Forderung
    Inventors: Armin Giese, Felix Schmidt, Christian Griesinger, Andrei Leonov, Sergey Ryazanov
  • WATER-SOLUBLE DERIVATIVES OF 3,5-DIPHENYL-DIAZOLE COMPOUNDS
    Publication number: 20180370997
    Abstract: The present invention is concerned with derivatives of 3,5-diphenyl-diazole compounds, which are effective therapeutic agents for use in treating diseases linked to protein aggregation and/or neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and Transmissible spongiform encephalopathies (TSEs) such as Creutzfeldt-Jakob disease (CJD). The therapeutic effect is caused by the inhibition of the protein aggregation in the affected tissue, such as the brain. 3,5-Diphenyl-diazole derivatives have been shown to be effective in inhibiting aggregation of proteins but are also characterized by their poor solubility in aqueous solutions. The prodrugs of the invention are modified 3,5-diphenyl-diazole derivatives, which are characterized by their improved solubility in aqueous solutions, and by their increased bioavailability.
    Type: Application
    Filed: December 14, 2016
    Publication date: December 27, 2018
    Applicants: Max-Planck-Gesellschaft zur Förderung
    Inventors: Armin GIESE, Felix SCHMIDT, Christian GRIESINGER, Andrei LEONOV, Sergey RYAZANOV
  • DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES
    Publication number: 20180346426
    Abstract: The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed.
    Type: Application
    Filed: August 3, 2018
    Publication date: December 6, 2018
    Applicants: LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN, MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSC HAFTEN E.V.
    Inventors: Armin GIESE, Uwe BERTSCH, Hans KRETZSCHMAR, Matthias HABECK, Thomas HIRSCHBERGER, Paul TAVAN, Christian GRIESINGER, Andrei LEONOV, Sergey RYAZANOV, Petra FRICK née WEBER, Markus GEISSEN, Martin H. GROSCHUP, Jens WAGNER
  • Drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
    Patent number: 10071966
    Abstract: The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: September 11, 2018
    Assignees: LUDWIG-MAXIMALIANS-UNIVERSITAT MUNCHEN, MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V.
    Inventors: Armin Giese, Uwe Bertsch, Hans Kretzschmar, Matthias Habeck, Thomas Hirschberger, Paul Tavan, Christian Griesinger, Andrei Leonov, Sergey Ryazanov, Petra Frick, Markus Geissen, Martin H. Groschup, Jens Wagner
  • DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES
    Publication number: 20160185730
    Abstract: The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed.
    Type: Application
    Filed: December 22, 2015
    Publication date: June 30, 2016
    Applicants: Ludwig-Maximilians-Universität München, Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
    Inventors: Armin Giese, Uwe Bertsch, Hans Kretzschmar, Matthias Habeck, Thomas Hirschberger, Paul Tavan, Christian Griesinger, Andrei Leonov, Sergey Ryazanov, Petra Frick née Weber, Markus Geissen, Martin H. Groschup, Jens Wagner
  • NEW DRUG FOR INHIBITING AGGREGATION OF PROTEINS INVOLVED IN DISEASES LINKED TO PROTEIN AGGREGATION AND/OR NEURODEGENERATIVE DISEASES
    Publication number: 20110293520
    Abstract: The present invention relates to a compound represented by formula (E). The present invention also relates to a compound represented by the formula (E) for use in the treatment or prevention of diseases linked to protein aggregation and/or neurodegenerative diseases. Moreover, the present invention relates to pharmaceutical and diagnostic compositions comprising the compound of the invention as well as to a kit. Furthermore, the present invention relates to a method of imaging deposits of aggregated protein. A kit for preparing a detectably labelled compound of the present invention is also disclosed. Formula (E) wherein X, Y and L are independently nondirectionally selected from —C(R1)(R2)—, —C(R3)?, —N(R4)—, —N?, —N+(R5)?, —O— and —S—; M and Z are independently nondirectionally selected from formula (I) and formula (II).
    Type: Application
    Filed: June 9, 2009
    Publication date: December 1, 2011
    Inventors: Armin Giese, Uwe Bertsch, Hans Kretzschmar, Mathias Habeck, Thomas Hirschberger, Paul Tavan, Christian Griesinger, Andrei Leonov, Sergey Ryazanov, Petra Weber, Markus Geissen, Martin H. Groschup, Jens Wagner
  • Systematic identification of new anti-prion drugs by high-throughput screening based on scanning for intensely fluorescent targets (sift)
    Publication number: 20100029773
    Abstract: The present invention relates to a method of identifying a compound for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases, comprising the steps of: (a) bringing into contact a labeled monomeric protein and a differently labeled aggregate of said protein in the (1) presence and (2) absence of a candidate inhibitor of aggregation, (b) determining the amount of co-localized labels, representing the extent of binding of the monomeric proteins to the aggregates of said protein; and (c) comparing the result obtained in the presence and absence of said compound, wherein a decrease of co-localized labels in the presence of said compound is indicative of the compound's ability to inhibit aggregation of said protein. Moreover, the present invention relates to a pharmaceutical composition containing said inhibitor of aggregation as well as to a kit.
    Type: Application
    Filed: May 24, 2005
    Publication date: February 4, 2010
    Applicants: LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN, MAX-PLANCK-GESELLSCHAFT FUR FORDERUNG DER WISSENSCHAFTEN E.V.
    Inventors: Uwe Bertsch, Armin Giese, Hans Kretzschmar, Paul Tavan, Thomas Hirschberger, Jan Bieschke, Petra Weber, Konstanze F. Winklhofer, Jörg Tatzelt, Ulrich F. Hartl, Gerda Mitterregger-Kretzschmar, Tobias Johannes Högen
  • Screening assay for aggregations
    Publication number: 20050147989
    Abstract: A method for the identification of substances for influencing aggregations comprising the following steps: a) combining at least one aggregate having a first detectable function and at least one monomer having a second detectable function, wherein said at least one monomer has an affinity for said at least one aggregate, in the presence of a potentially aggregation-influencing substance; b) determining a degree of labeling of the aggregates, the degree of labeling being a measure of the number and proportion of the detectable functions bound.
    Type: Application
    Filed: October 1, 2004
    Publication date: July 7, 2005
    Inventors: Uwe Bertsch, Armin Giese, Hans Kretzschmar, Jan Bieschke